236 related articles for article (PubMed ID: 27909835)
21. Impact of CINV in earlier cycles on CINV and chemotherapy regimen modification in subsequent cycles in Asia Pacific clinical practice.
Kim HK; Hsieh R; Chan A; Yu S; Han B; Gao Y; Baños A; Ying X; Burke TA; Keefe DM
Support Care Cancer; 2015 Jan; 23(1):293-300. PubMed ID: 25142702
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and safety of olanzapine combined with aprepitant, palonosetron, and dexamethasone for preventing nausea and vomiting induced by cisplatin-based chemotherapy in gynecological cancer: KCOG-G1301 phase II trial.
Abe M; Hirashima Y; Kasamatsu Y; Kado N; Komeda S; Kuji S; Tanaka A; Takahashi N; Takekuma M; Hihara H; Ichikawa Y; Itonaga Y; Hirakawa T; Nasu K; Miyagi K; Murakami J; Ito K
Support Care Cancer; 2016 Feb; 24(2):675-682. PubMed ID: 26130365
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of risk factors predicting chemotherapy-related nausea and vomiting: results from a European prospective observational study.
Molassiotis A; Aapro M; Dicato M; Gascon P; Novoa SA; Isambert N; Burke TA; Gu A; Roila F
J Pain Symptom Manage; 2014 May; 47(5):839-848.e4. PubMed ID: 24075401
[TBL] [Abstract][Full Text] [Related]
24. Rationale and design of the Pan Australasian chemotherapy-induced emesis burden of illness study.
Keefe DM; Chan A; Kim HK; Hsieh RK; Yu S; Wang Y; Nicholls RJ; Burke TA
Support Care Cancer; 2015 Jan; 23(1):253-61. PubMed ID: 25115893
[TBL] [Abstract][Full Text] [Related]
25. Treatment of Breakthrough and Refractory Chemotherapy-Induced Nausea and Vomiting.
Navari RM
Biomed Res Int; 2015; 2015():595894. PubMed ID: 26421294
[TBL] [Abstract][Full Text] [Related]
26. Perception of healthcare providers versus patient reported incidence of chemotherapy-induced nausea and vomiting after the addition of NK-1 receptor antagonists.
Majem M; Moreno ME; Calvo N; Feliu A; Pérez J; Mangues MA; Barnadas A
Support Care Cancer; 2011 Dec; 19(12):1983-90. PubMed ID: 21086141
[TBL] [Abstract][Full Text] [Related]
27. Effectiveness of palonosetron versus other serotonin 5-HT3 receptor antagonists in triple antiemetic regimens during multiday highly emetogenic chemotherapy.
Kim KI; Lee DE; Cho I; Yoon JH; Yoon SS; Lee HS; Oh JM
Ann Pharmacother; 2012 Dec; 46(12):1637-44. PubMed ID: 23170032
[TBL] [Abstract][Full Text] [Related]
28. Pathogenesis-based treatment of chemotherapy-induced nausea and vomiting--two new agents.
Navari RM
J Support Oncol; 2003; 1(2):89-103. PubMed ID: 15352652
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of the validity of chemotherapy-induced nausea and vomiting assessment in outpatients using the Japanese version of the MASCC antiemesis tool.
Matsuda Y; Okita K; Furuhata T; Kutomi G; Yamashita K; Sato Y; Takimoto R; Hirata K
Support Care Cancer; 2015 Nov; 23(11):3331-9. PubMed ID: 26003425
[TBL] [Abstract][Full Text] [Related]
30. Use of neurokinin-1 receptor antagonists in patients receiving moderately or highly emetogenic chemotherapy.
Rogers MP; Blackburn L
Clin J Oncol Nurs; 2010 Aug; 14(4):500-4. PubMed ID: 20682506
[TBL] [Abstract][Full Text] [Related]
31. Palonosetron plus dexamethasone effectively prevents acute and delayed chemotherapy-induced nausea and vomiting following highly or moderately emetogenic chemotherapy in pre-treated patients who have failed to respond to a previous antiemetic treatment: comparison between elderly and non-elderly patient response.
Massa E; Astara G; Madeddu C; Dessì M; Loi C; Lepori S; Mantovani G
Crit Rev Oncol Hematol; 2009 Apr; 70(1):83-91. PubMed ID: 18723369
[TBL] [Abstract][Full Text] [Related]
32. Analysis of aprepitant for prevention of chemotherapy-induced nausea and vomiting with moderately and highly emetogenic chemotherapy.
Molassiotis A; Nguyen AM; Rittenberg CN; Makalinao A; Carides A
Future Oncol; 2013 Oct; 9(10):1443-50. PubMed ID: 23987791
[TBL] [Abstract][Full Text] [Related]
33. How to improve the prevention of chemotherapy-induced nausea and vomiting? The French NAVI study.
Vanbockstael J; Coquan E; Gouerant S; Allouache D; Faveyrial A; Noal S; Delcambre C; Galais MP; Héron JF; Lefebvre AC; Sevin E; Hrab I; Polycarpe F; André M; Kaluzinski L; Gervais R; Gunzer K; Vié B; Saucier G; Lemenand N; Grellard JM; Clarisse B; Dugué AE; Joly F
Support Care Cancer; 2016 Mar; 24(3):1131-8. PubMed ID: 26268784
[TBL] [Abstract][Full Text] [Related]
34. Feasibility of using the Multinational Association of Supportive Care in Cancer Antiemesis Tool for assessment of chemotherapy-induced nausea and vomiting at the Tom Baker Cancer Centre.
Warr JK; Chambers CR; Cusano FL; Cuthbert CA; Mah MS
J Oncol Pharm Pract; 2015 Oct; 21(5):348-57. PubMed ID: 24938292
[TBL] [Abstract][Full Text] [Related]
35. The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): the Pan European Emesis Registry (PEER).
Aapro M; Molassiotis A; Dicato M; Peláez I; Rodríguez-Lescure Á; Pastorelli D; Ma L; Burke T; Gu A; Gascon P; Roila F;
Ann Oncol; 2012 Aug; 23(8):1986-1992. PubMed ID: 22396444
[TBL] [Abstract][Full Text] [Related]
36. The efficacy of oral ondansetron and dexamethasone for the prevention of acute chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy - a retrospective audit.
Ng WL; Della-Fiorentina SA
Eur J Cancer Care (Engl); 2010 May; 19(3):403-7. PubMed ID: 19686353
[TBL] [Abstract][Full Text] [Related]
37. Adherence to antiemetic guidelines in solid cancer patients receiving highly emetogenic chemotherapy in Korea.
Lee R; Ku M; Je NK
Support Care Cancer; 2024 Feb; 32(3):190. PubMed ID: 38400861
[TBL] [Abstract][Full Text] [Related]
38. Cost-effectiveness of aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with highly emetogenic chemotherapy.
Moore S; Tumeh J; Wojtanowski S; Flowers C
Value Health; 2007; 10(1):23-31. PubMed ID: 17261113
[TBL] [Abstract][Full Text] [Related]
39. Incidence and predictors of anticipatory nausea and vomiting in Asia Pacific clinical practice--a longitudinal analysis.
Chan A; Kim HK; Hsieh RK; Yu S; de Lima Lopes G; Su WC; Baños A; Bhatia S; Burke TA; Keefe DM
Support Care Cancer; 2015 Jan; 23(1):283-91. PubMed ID: 25112561
[TBL] [Abstract][Full Text] [Related]
40. Chemotherapy-induced nausea and vomiting and antiemetic prophylaxis with palonosetron versus other 5-HT3 receptor antagonists in patients with cancer treated with low emetogenic chemotherapy in a hospital outpatient setting in the United States.
Schwartzberg L; Morrow G; Balu S; Craver C; Gayle J; Cox D
Curr Med Res Opin; 2011 Aug; 27(8):1613-22. PubMed ID: 21696263
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]